Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Comment by ScienceFirston Apr 13, 2023 7:26am
230 Views
Post# 35392372

RE:Looked at Q3 filing on Sedar again

RE:Looked at Q3 filing on Sedar againN0taP00p ... Calm down.  And stop trying to come with all sorts of negative scenarios.  You've often been wrong in the past.

TLT management brought us here, on a shoestring budget and have always solve issues.  TLT is no different than any other SMB or biotechs; it has to manage the burn rate.  And if you understand the micro and macro environment of biotechs, you'll admit that financing has not been obvious for any of them in the last 3y.

I know you graduated from Bungee's kindergarten with FGPstuck with your "respect the shareholders" mantra but we all know what are the next steps for this company.  But you're asking for info. that you wouldn't even divulge yourself if you were at the head of a competitive smb.  So just grow on the maturity side as TLT management is competent enough to know what they have to do to get us there.  You, not so much.  Playing the armchair quarterback like you do is so easy.
<< Previous
Bullboard Posts
Next >>